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A great variety of non-specific symptoms may occur in patients living or working in 
moisture-damaged buildings. In the beginning, these symptoms are usually reversible, 
mild, and present irritation of mucosa and increased morbidity due to respiratory tract 
infections and asthma-like symptoms. Later, the disease may become chronic and a 
patient is referred to a doctor where the assessment of dampness and mold hypersen-
sitivity syndrome (DMHS) often presents diagnostic challenges. Currently, unanimously 
accepted laboratory tests are not yet available. Therefore, the diagnosis of DMHS is 
clinical and is based on the patient’s history and careful examination. In this publication, 
I reviewed contemporary knowledge on clinical presentations, laboratory methods, 
and clinical assessment of DMHS. From the literature, I have not found any proposed 
diagnostic clinical criteria. Therefore, I propose five clinical criteria to diagnose DMHS: 
(1) the history of mold exposure in water-damaged buildings, (2) increased morbidity 
to due infections, (3) sick building syndrome, (4) multiple chemical sensitivity, and 
(5) enhanced scent sensitivity. If all the five criteria are met, the patient has a very prob-
able DMHS. To resolve the current problems in assigning correct DMHS diagnosis, we 
also need novel assays to estimate potential risks of developing DMHS.
Keywords: mold, dampness, multiple chemical sensitivity, sick building syndrome, clinical classification, 
HLA genes
inTRODUCTiOn
There is growing variety of clinical symptoms related to the poor indoor air quality, especially in 
water-damaged buildings infested by hazardous microbiota (1). As a rule, dampness and mold 
hypersensitivity syndrome (DMHS), as we call this clinical condition here presents with signs 
of irritation of the respiratory tract and/or the eyes. Subsequently, the patient may experience 
recurrent sinusitis or bronchitis and neurological manifestations, such as headaches, nausea, 
and unexplained fatigue. Some may develop rheumatic symptoms resembling fibromyalgia or 
neurological symptoms may progress into pains and/or numbness in the legs and arms and the 
so-called brain fog (2–4). Some patients develop newly onset asthma, or may present asthma-like 
conditions, such as dyspnea, burning sensation in the respiratory tract, and productive or non-
productive cough.
TAbLe 1 | Questionnaire to the exposed patients.
The patient is asked whether the following chemicals have explicitly an irritation 
action on them:
 1. Perfumes
 2. Deodorants, shaving lotion
 3. Detergents
 4. Tobacco smoke or other heavy smoke
 5. Fresh printed matters like newspapers
 6. Paints, varnishes, glues
 7. Hairdresser’s products
 8. Different dusts, especially street dust
 9. Exhaust fumes, gasoline, oil, other traffic fumes
 10. Windshield detergent
 11. Formaldehyde or some other known chemical
 12. Spices or some other food products
If four or more chemicals, at least in four of the abovementioned groups, explicitly 
irritate, the diagnosis of multiple chemical sensitivity is probable.
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THe nATURAL COURSe OF THe DMHS
There is a huge variation in the time preceding the onset of 
symptoms in individuals who lived or worked in environment 
contaminated with moisture-related microbiota. The time 
interval can vary from a few months to several years. It is not 
known which factors may contribute to individual susceptibility 
to DMHS. It seems that cumulative exposure time during an 
individual’s lifespan when he/she is exposed to dampness micro-
biota may be a decisive factor. The age of the person when he/she 
will be exposure to moisture microbiota for the first time may 
be another critical component. One may speculate that there are 
several genetic factors, some of which are protective and some are 
permissive, that might contribute to the development of DMHS.
As a rule, DMHS begins with symptoms of irritation in eyes, 
nose, and respiratory tract. The eyes are itchy and reddened, the 
nose is blocked, sneezing, and cough are common symptoms at 
the beginning. An important hallmark of DMHS, as in many 
other diseases associated with poor indoor air quality, is the so-
called sick building syndrome (SBS) (5). This syndrome means 
that a patient experiences aggravation or onset of symptoms 
when entering a certain water-damaged building. However, when 
he/she leaves the building the symptoms may be relieved or disap-
pear completely. In the early phase of DMHS, the symptoms of 
SBS may disappear totally when he/she can avoid staying in the 
building for 1 or 2 days but the time period for total recovery 
seems to become prolonged with each new exposure until, finally, 
the symptoms will become irreversible even though the patient 
no longer visits the water-damaged building. Some unknown 
factors seem to trigger disease chronic course.
Dampness and mold hypersensitivity syndrome patients have 
increased morbidity rate due to infections of respiratory tract, 
e.g., recurrent sinusitis, bronchitis even pneumonias when the 
exposure to moldy environment continues. The disease seems 
to progresses from irritation to recurrent infections, such as 
tonsillitis, reactivations of herpes simplex virus (HSV1 and 
HSV2), recurrent urinary tract, skin infections, etc. Patients may 
experience also episodes of mild, prolonged fever and fatigue and 
a minority of them may develop the so-called chronic fatigue 
syndrome (6, 7).
Patients may complain muscle and joint pain resembling 
fibromyalgia. Furthermore, some other rheumatic manifestations 
have rarely been described in patients with DMHS (8, 9). Some 
patients develop functional central nervous system symptoms 
that are often called “brain fog” (2–4). These patients have 
impaired cognition, inability to concentrate, and problems with 
both short- and long-term memories. Occasional headaches and 
dizziness are also common in “brain fog.” Peripheral neurological 
manifestations, such as transient pains and numbness in the legs 
and/or arms are also reported by DMHS patients.
Dyspnea, burning pain, and irritation in the respiratory tract 
are very common although the variations in the peak expiratory 
flow (PEF) value do not fulfill classic asthma criteria. Instead, 
asthma-like dyspnea with mildly lowered PEF value variation that 
does not meet the diagnostic criteria of asthma is more common. 
However, the risk to develop unambiguous asthma is increased if 
the exposure to dampness microbiota continues (10). Abdominal 
symptoms related to DMHS are indistinguishable from irritable 
colon. Many different types of skin rashes are also common, even 
vasculitis-like lesions may occasionally occur (11).
According to my clinical experience (more than 1,000 DMHS 
patients), approximately every second DMHS patient will, finally, 
develop multiple chemical sensitivity (MCS) or chemical intoler-
ance syndrome. MCS is a condition when a person experiences 
a complex array of recurrent unspecific symptoms attributable 
to low dosages of chemicals that are well tolerated by most peo-
ple (11). Although many biomarkers of inflammation can be 
detected, there is no single-specific diagnostic laboratory test to 
diagnose MCS at the moment (12). The diagnosis of MCS can be 
only established by questionnaire and applying varying clinical 
definitions (13–15).
As far as I am aware, at the moment, there are no reliable 
epidemiological studies that would link mold-related disease 
to MCS. The incidence of this co-morbidity seems not yet to be 
reported in the literature. However, there are many symptoms 
that are common in both conditions, such as asthma, hay fever, 
allergic, and rheumatic symptoms (11, 15). As a rule, MCS 
seems to develop after the development of the so-called SBS but 
occasionally MCS may occur even without documented exposure 
to dampness microbiota or any history of preceding SBS. In my 
clinical practice to diagnose MCS, I used criteria described in 
the Table 1.
Electromagnetic field sensitivity (EMS) has been reported 
to associate strongly with chemical sensitivity (16). According 
to my clinical experience, DMHS occurs first, then MCS may 
develop in approximately half of those patients, and finally 
approximately one quarter of the DMHS patients will develop 
EMS. Only very rare EMS will develop without DMHS or with-
out MCS.
SeROLOGiCAL ASSAYS TO ObTAin 
eviDenCe OF DMHS
Serology has been used for decades to support the diagnosis of 
mold-related disease. IgG and IgE responses have been most 
extensively studied, although there are clinical reports of a 
TAbLe 2 | Clinical criteria for dampness and mold hypersensitivity syndrome 
(DMHS).
If all the five criteria are met, the patient has very probably DMHS; if four to three 
criteria are met the diagnosis of DMHS is probable; and if two criteria are met 
and typical clinical symptoms, the diagnosis of DMHS is possible:
 1. History of mold exposure in water-damaged buildings with or without any 
symptoms.
 2. Increased morbidity due to infections. This is an early stage of the disease.
 3. Suffering the so-called sick building syndrome. That means that a person may 
feel unwell when entering a water-damaged building but the symptoms relieve 
or disappear when being outside the problematic building from 1 to 2 days.
 4. Development of the multiple chemical sensitivity (see Table 1).
 5. Increased scent sensitivity compared to his/her healthy stage. The patient 
may report ability to smell moldy odor, e.g., from clothes of a nearby standing 
person.
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lack of any association between IgG antibodies and exposure 
to molds (17). Also, IgE-mediated sensitization and skin prick 
positivity for molds are rare (18). However, by using commercial 
antigens derived from Penicillium notatum, Aspergillus niger, 
and Stachybotrys chartarum, specific IgG-, IgM-, and IgA-class 
antibodies were elevated in patients compared to the controls 
(n =  500) (19). On the other hand, it was reported that clini-
cal symptoms did not always correlate with the mold antibody 
levels (20). There are promising results from mold-specific 
saliva immunoglobulins against mycotoxin structures in a study 
that compared their levels in exposed individuals and controls 
(21). However, the authors noted that genetic differences in 
cytochrome P450 enzymes activities or glutathione S-transferase 
might be responsible for an individual’s vulnerability to disease 
(20). This suggests that in DMHS immunological response is 
multifactorial and explains the difficulty in exploiting serology 
for diagnosis.
The use of serology to support diagnosis of DMHS is prob-
lematic for several reasons. First, mold infestation is a dynamic 
ecological microenvironment where the relative quantities of 
different species may vary at different time points. This ecological 
system may contain not only fungi but also Gram-positive and 
Gram-negative bacteria. In addition, bioorganic compounds 
emitted from the decay and breakdown of supporting building 
material may contribute to the immunological response. Second, 
it is well known that many highly organized microbiological spe-
cies can change their surface antigens to ensure adaptation and 
escape inactivation by the host’s immune system. For example, 
Borrelia species and parasites such as Trypanosoma cruzi or 
Plasmodium species have been demonstrated to modify their 
antigenic structures during infection (22), and several studies 
have revealed how the secretion of fungal antigens becomes 
altered in various conditions (23). These factors represent one 
of the greatest challenges in the development of mold-specific 
diagnostics. For this reason, it would be preferable that the tested 
antigens should be prepared from the suspected buildings (20), 
but this is unpractical in clinical settings. Third, the immunologi-
cal insult from environmental molds may cause either activation 
or deprivation of the host immunologic system (24–26). It is 
especially notable that mycotoxins such as gliotoxin can inhibit 
the activity of antigen-presenting cells and limit the amount 
and functions of monocytes and simply kill immune cells and, 
thus, disarm the body’s immune response (25). Furthermore, 
decreased immunoglobulin production may be observed in some 
of heavily exposed individuals. It would be of interest to study 
whether or not the most potent mycotoxin-producing strains are 
responsible for the reduction of antibody production. Therefore, 
it seems apparent that novel alternative to conventional serology 
diagnostic approaches are required.
PReSenTATiOn OF CLiniCAL 
DiAGnOSTiC CRiTeRiA FOR DMHS
It is a clinical reality of today that there are no accepted diagnostic 
criteria for DMHS. Here, on the basis of my clinical expertise, 
I suggest criteria for consideration by international medical 
community, Table 2.
The first criterion: there should be an evidence of periods of 
patient being exposed to moisture microbes during his/her life-
time even without symptoms, i.e., when he/she has been living 
or working in water-damaged houses. Patients can recall if they 
have been living or working in the houses with leaking roofs or 
windows such that rain can enter or there has been flooding, i.e., 
conditions suitable for the growth of molds. Visible mold or mold 
odor in indoor air are also probable indicators for the presence 
of moisture microbiota even without microbiological culture 
confirmation. There is a reasonable correlation between the odor 
of molds in indoor air and quantitatively measured microbial 
exposure in homes (27). Importantly, microbiological culture 
reports unavailability by the time of the patients’ visit should not 
delay their medical consultation.
The second criterion is increased morbidity due to infectious 
diseases that are observed in a previously healthy person. Small 
children likewise adults or even pets may present with increased 
rate of, e.g., tonsillitis, bronchitis, skin and eye infections, and 
sinusitis. Especially, when a person might have more than three 
sinusitis/year, the doctor might start to suspect environmental 
factors. In the beginning, the patients or the guardians of small 
children may not associate the high rate of their visits to the 
doctors due to these infections. This phase is associated with the 
increased frequency of sick leaves. This is an early stage of DMHS, 
and the only way to prevent the development of the chronic 
course is to acknowledge the possibility of moldy environment 
and start timely investigations. However, this stage of the disease 
if often overlooked.
The third criterion is that the patient has a history of the so-
called SBS. The patient notices that his/hers symptoms worsen 
when he/she enters the problematic building and conversely, the 
symptoms diminish when they are not in the building. If there 
is a clear history of leaky roofs or rain or moisture gaining or a 
clear odor of mold or visible molds in ceilings or walls, it is not 
necessary to have culture confirmation of moisture microbes. If 
molds and other typical moisture bacteria can be cultured from 
the structures of the problem building or high concentrations of 
volatile organic compounds can be detected in the indoor air, this 
raises the probability of the DMHS diagnosis.
The forth criterion is the development of MCS. I used self-
made questionnaire (Table  1) to diagnose MCS. If the patient 
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reacts (i.e., he/she is explicitly irritated) to four or more chemicals 
belonging to at least four different groups (Table  1), then the 
diagnosis of MCS is probable. The definition of what is interpreted 
as “explicitly irritates” is important, because it has an effect on the 
incidence of MCS at the population level. If the patient experi-
ences such symptoms as nausea, headache, cough, or dyspnea, or 
the patient has to distance him/herself e.g., from a person using 
deodorants, this means indication for “explicitly irritation.”
And lastly, the fifth criterion is an enhanced sensitivity to 
odors, especially the odor of molds. For example, if the patient 
can smell the odor of molds from the clothes of a nearby person, 
this can be viewed as the positive fifth criterion.
The presence of all the five criteria (Table  2) designates 
advanced stage of DMHS that have been lasted for at least many 
months or even years. In this situation, we have probably lost the 
time window of opportunities to completely revert the disease. 
The first limitation of this approach is that it will not pick up per-
sons at the early stages of the disease and, second, that it cannot 
be used in very young children because the questionnaire is not 
applicable.
If a person has all the five of the abovementioned criteria, 
then the diagnosis of DMHS is very probable. The presence of 
the four to three positive criteria means probable DMHS and the 
two positive criteria means possible DMHS.
ASSAYS OF MYCOTOXin AnD 
neUROLOGiCAL SYMPTOMS
In invasive aspergillosis, the diagnosis often relies on methods 
detecting either living fungi in blood or deep tissue specimens, 
or specific antibodies or fungal antigens (23) or DNA. As a novel 
approach, one may mention measurements of fungal second-
ary metabolite signatures from exhaled breath (28). An indoor 
toxicity method (29) is a novel adjunct to diagnostics. Assays to 
detect mycotoxins in serum (30) and the detection of the excreted 
mycotoxins (e.g., urine, saliva) (31–34) may be specific diagnostic 
tests to detect DMHS. The test should be also sensitive and robust 
to be incorporated into diagnostic criteria.
One potential way to improve diagnostics would be the assays 
originally designed for neurologic patients with e.g., polyneu-
ropathies to detect antibodies against neural structures, such as 
gangliosides, myelin-associated glycoprotein and chondroitin 
sulfate, and so on (35). On the other hand, it is known that low 
titer levels of antinuclear antibodies, rheumatoid factors, and 
other autoantibodies are non-specific and can be detected in many 
chronic infections or even aging, or neuropathies of autoimmune 
origin (36).
nOveL LAbORATORY MeTHODS TO FinD 
THOSe wHO ARe AT RiSK TO DeveLOP 
DMHS
The major histocompatibility complex (MHC), located on 
chromosome 6 p-arm 21.3, and the genes in the HLA region are 
more important determinants of autoimmune or inflammatory 
disorders than any other region in the human genome (37). 
Therefore, the immunogenetics possibly linked to genes in HLA 
area of chromosome 6 could possibly be used to assess individual 
risk to develop DMHS. There are a few studies examining how 
deficiency of the complement system would influence an indi-
vidual’s susceptibility to mold exposure. Normally, there are two 
complement 4A and 4B genes, but the variation in the number of 
C4 genes is common. Less than two complement 4A or 4B genes 
are common in Finland (11 and 41%, respectively). Complement 
4A CTins mutation (6%) is responsible for non-functional com-
plement 4A gene, causing the incidence for non-functional C4A 
up to 17% (17). Therefore, this particular mutation might have 
harmful consequences to rather large sections of the Finnish 
population, from which 0.8/5.5 million inhabitants have been 
estimated to be exposed repeatedly to molds. Support for the 
important role of HLA genes is the fact that activated T  cells 
(CD3+ CD26+ cells) and the class II major histocompatibility 
molecule MHC (CD3+ HLA-DR+) are found in over 90% of the 
mold exposed individuals when compared to the controls (34).
Missing HLA genes or a deficiency in function of these 
genes represent a further risk in those individuals who are mold 
exposed. Unfortunately, the genotyping of the traditional HLA 
genes is expensive and laborious, which may limit the feasibility 
of these markers (37).
DiReCTiOnS FOR THe DiAGnOSiS AnD 
TReATMenT OF DMHS
Sensitive and specific laboratory tests for the diagnosis of 
DMHS are definitely needed; however, it may turn out that 
expectations of clinicians to have only one test of high sensitiv-
ity and specificity are never met (38). For example, diagnosis 
of autoimmune diseases is based on a combination of clinical 
presentations supplemented by several diagnostic methods. 
It may be more realistic that a useful combination of different 
laboratory algorithms will be used in extended DMHS criteria. 
As explained above, serological testing has limitations due to 
high variability of species, antigens, and their cross-reactivities 
(39). Nonetheless, sensitive commercial serological IgG tests and 
basophil activation testing for chronic pulmonary aspergillosis 
(CPA) present some promise (40–42). From a clinical point of 
view, it is probable that there is some overlap between allergic 
bronchopulmonary mycosis, allergic bronchopulmonary 
aspergillosis, CPA, and DMHS (40), which should be taken 
into account when epidemiological studies on mold allergy are 
conducted in the future.
According to my experience, corroborated by others (43–48), 
successful cure can be achieved only if the treatment starts early 
enough, and the patient avoids problematic moisture-damaged 
building already when experiencing higher morbidity with infec-
tions and the SBS stage without yet an onset of MCS that may 
follow later. In the early stages of the disease, the patient may 
become completely asymptomatic as long as he/she continues 
avoiding re-exposures. Challenge to achieve complete cure 
becomes more demanding in patients with fully blown MCS. In 
these situations, any re-exposure may occur by chance almost 
anywhere any time and not necessarily in moldy environment. 
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Patients’ symptoms could be impossible to link to any preceding 
exposure to water-damaged building. Thus, avoidance of moldy 
buildings is recommended to patients with SBS.
Empirically, the majority of DMHS patients are recommended 
to adhere to a low carbohydrate diet. However, I am not aware of 
any studies on the effect of different diets on the clinical course 
of DMHS. In addition, many DMHS patients consume large 
amounts of l-cysteine amino acid or N-acetylcysteine (NAC) 
and they report that they may feel better, especially their “brain 
fog” symptoms are relieved, at least to some extent. This treat-
ment was not yet studied systematically in controlled studies. 
However, there are studies suggesting that NAC might be effective 
in patients with different neurological symptoms (49).
COnCLUSiOn
It is undisputable that, at the moment, available laboratory meth-
ods do not fully support clinical practice. Prevention and treat-
ment of DMHS would largely benefit from improved laboratory 
diagnostics because it may facilitate early intervention. Clinical 
criteria of DMHS are now presented for the first time. These crite-
ria comprise five positions, and the assessment of the probability 
levels on the basis of the fulfillment of these criteria is discussed.
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